Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis.
The aim of this study was to determine if substitution of daily methadone with second daily levo-alpha-acetylmethadol (LAAM) would convert non-holders on methadone into holders on LAAM, and to compare plasma concentration-time profiles of (R)-methadone with LAAM and its two metabolites. Sixteen stable methadone maintenance treatment participants (non-holders, n = 8) were randomly allocated to continue methadone for 3 months or switch to LAAM for 3 months, and then crossed over to the alternative drug for 3 months. At steady state, there were two testing sessions (24 h for methadone and 48 h for LAAM), during which opioid withdrawal severity, respiration rate and pupil diameter were measured 10-11 times and venous blood was collected 13-15 times. Ten age- and gender-matched controls underwent one 48-h test session. Areas under the withdrawal severity score versus time curve (AUC(0-47) hours for LAAM and controls; AUC(0-24) x 2 for methadone) were similar in holders on methadone and LAAM (P = 0.62), but were greater in non-holders when they were taking methadone than LAAM (P < 0.001). Respiratory depression and pupillary constriction were similar for LAAM and methadone. In comparison to (R)-methadone, plasma nor- and dinor-LAAM concentrations fluctuated little over the dosing interval. LAAM converted methadone non-holders into LAAM holders. LAAM may therefore be useful in selected MMT non-holders and improve retention in opioid treatment programs.
Newcombe
David A L
DA
Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide 5005, Australia.
Bochner
Felix
F
White
Jason M
JM
Somogyi
Andrew A
AA
D000328:Adult; D000704:Analysis of Variance; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D008297:Male; D008691:Methadone / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008692:Methadyl Acetate / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008875:Middle Aged; D009293:Opioid-Related Disorders / Q000097:blood / Q000523:psychology / Q000534:rehabilitation; D013375:Substance Withdrawal Syndrome / Q000097:blood / Q000188:drug therapy* / Q000523:psychology
D008692:Methadyl Acetate; D008691:Methadone